Estradiol phosphate | 4995-43-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Estradiol phosphate
• 英文别名: 17β-phosphonooxy-estra-1,3,5(10)-trien-3-ol；17β-Phosphonooxy-oestra-1,3,5(10)-trien-3-ol；(8R)-3-Hydroxy-17c-phosphonooxy-13c-methyl-(8rH.9tH.14tH)-7.8.9.11.12.13.14.15.16.17-decahydro-6H-cyclopenta[a]phenanthren；Phosphorsaeure-mono-[3-hydroxy-oestratrien-(1.3.5(10))-yl-(17β)-ester]；17β-Phosphonooxy-oestratrien-(1.3.5(10))-ol-(3)；17β-Phosphonooxy-oestratrien-(A)-ol-(3)；[(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] dihydrogen phosphate
• CAS: 4995-43-1
• 化学式: C₁₈H₂₅O₅P
• 分子量: 352.367
• InChiKey: BBWXLCKRYRQQPL-ZBRFXRBCSA-N

物化性质

• 熔点：
  216-217 °C
• 沸点：
  561.9±60.0 °C(Predicted)
• 密度：
  1.37±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  87
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  雌二醇 在 四磷十氧化物 作用下， 以 甘油 为溶剂， 反应 1.0h， 生成 Estradiol phosphate
  参考文献：
  名称：

  [EN] PROCESS
  [FR] PROCÉDÉ

  摘要：

  一种高效商业化的磷酸酯化过程，用于复杂醇类（如二级和三级醇），在高温下使用P4O10，以及该过程得到的产品。

  公开号：

  WO2018112512A1

文献信息

• Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US10793545B2

  公开（公告）日：2020-10-06

  The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.

  本申请涉及新型取代吲唑、其制备工艺、其单独使用或组合使用以治疗和/或预防疾病，以及其用于生产治疗和/或预防疾病的药物，特别是用于治疗和/或预防子宫内膜异位症、子宫内膜异位症相关疼痛和其他子宫内膜异位症相关症状，如痛经、淋巴瘤、类风湿性关节炎、脊柱关节炎（尤其是银屑病性脊柱关节炎和 Bekhterev 病）、红斑狼疮、多发性硬化症、黄斑变性、慢性阻塞性肺病、痛风、脂肪肝、胰岛素抵抗、肿瘤性疾病和银屑病。
• Time-release and micro-dose formulations for topical application of estrogen and estrogen analogs or other estrogen receptor modulators in the treatment of dry eye syndrome, and methods of preparation and application
  申请人：Redwood Pharma AB

  公开号：US10799446B2

  公开（公告）日：2020-10-13

  A topical application formulation of estrogen and estrogen analogs or other estrogen receptor modulators is disclosed for the treatment of primary or secondary dry eye syndrome (also known as keratoconjunctivitis sicca (KCS)). Preferred formulations include 17-β-estradiol and its derivatives in lipid, liposomes, polymers, or aqueous or non-aqueous vehicles for the topical treatment of the ocular surface tissues particularly as time-release or micro-dose formulations. These formulations may also be useful in treating other conditions where KCS may occur, such as post-operative refractive surgery and corneal transplant patients.

  本发明公开了一种雌激素和雌激素类似物或其他雌激素受体调节剂的局部应用制剂，用于治疗原发性或继发性干眼综合征（又称角结膜炎（KCS））。优选制剂包括脂质、脂质体、聚合物或水性或非水性载体中的 17-β-estradiol 及其衍生物，用于眼表组织的局部治疗，特别是作为缓释或微剂量制剂。这些制剂还可用于治疗可能发生 KCS 的其他病症，如屈光手术后和角膜移植患者。
• Method to potentiate the therapeutic efficacy of taxane and derivatives thereof
  申请人：——

  公开号：US20030153539A1

  公开（公告）日：2003-08-14

  The use of estramustine phosphate and its metabolites estramusfine and estromustine allow to potentiate the therapeutic efficacy of taxanes by both improving their pharmacokinetic and pharmacodynamidc profile through the inhibition of (CYP)2C8 and (CYP)3A4 enzymes, both responsible for the metabolism of the taxanes; formulations of estramustine phosphate and metabolites, combinations of these latter with taxanes and therapeutic methods of treatment comprising them as a combined therapy are also disclosed.

  通过抑制(CYP)2C8和(CYP)3A4酶（这两种酶都负责紫杉类药物的代谢），改善紫杉类药物的药代动力学和药效学特征，使用磷酸雌莫司汀及其代谢物雌莫司汀和雌莫司汀可以增强紫杉类药物的疗效；还公开了磷酸雌莫司汀及其代谢物的制剂、这些代谢物与紫杉类药物的组合以及将它们作为联合疗法的治疗方法。
• Transdermal transport of compounds
  申请人：West Michael Simon

  公开号：US20050089495A1

  公开（公告）日：2005-04-28

  There is provided a topical formulation comprising an effective skin-penetrating amount of one or more phosphate derivatives of one or more pharmaceutical hydroxy compounds and an acceptable carrier.

  本文提供了一种局部制剂，它包含有效皮肤渗透量的一种或多种药用羟基化合物的磷酸酯衍生物和可接受的载体。
• Pharmaceutically acceptable carrier for ophthalmic compositions
  申请人：Du Mee P. Charles

  公开号：US20060210645A1

  公开（公告）日：2006-09-21

  A pharmaceutically acceptable carrier for ophthalmic compositions useful in treating or alleviating the symptoms of dry eye syndrome, elevated intra-ocular pressure, age-related maculopathy or age-related macular degeneration.

  一种药学上可接受的载体，用于治疗或缓解干眼症、眼压升高、老年性黄斑病变或老年性黄斑变性症状的眼科组合物。